PharmaMar’s lurbinectedin granted orphan drug designation by FDA for small cell lung cancer treatment
Spanish pharmaceutical company PharmaMar has announced that its cancer drug, lurbinectedin, has received orphan drug designation from the US Food and Drug Administration (FDA) for ... Read More
AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ... Read More
Vyriad and Merck launch Phase 1 trial for innovative immuno-oncology drug combination
Vyriad, a US-based biotech company, has partnered with Germany's Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the ... Read More
FDA removes clinical hold on Advaxis’ Axalimogene Filolisbac, Durvalumab combo trial
Advaxis, a biotech firm based in New Jersey, announced a significant regulatory update as the U.S. Food and Drug Administration (FDA) has lifted the clinical ... Read More
Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors
Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More
Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer ... Read More
Seattle Genetics to acquire Cascadian Therapeutics for $614m to bolster oncology portfolio
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio ... Read More
Roche to acquire Ignyta for $1.7bn to enhance oncology portfolio
Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion ... Read More
Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative ... Read More
Novartis to acquire Advanced Accelerator Applications for $3.9bn to enhance oncology portfolio
Novartis, the Switzerland-based global healthcare giant, has announced its decision to acquire Advanced Accelerator Applications (AAA), a French radiopharmaceutical company, for $3.9 billion. This acquisition ... Read More